These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 3397998

  • 1. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
    Epand RM, Epand RF, Stafford AR, Orlowski RC.
    J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
    [Abstract] [Full Text] [Related]

  • 2. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
    Orlowski RC, Epand RM, Stafford AR.
    Eur J Biochem; 1987 Jan 15; 162(2):399-402. PubMed ID: 3803393
    [Abstract] [Full Text] [Related]

  • 3. Conformational and biological properties of partial sequences of salmon calcitonin.
    Epand RM, Stahl GL, Orlowski RC.
    Int J Pept Protein Res; 1986 May 15; 27(5):501-7. PubMed ID: 3733320
    [Abstract] [Full Text] [Related]

  • 4. des-Ser2 salmon calcitonin: a biologically potent synthetic analog.
    Schwartz KE, Orlowski RC, Marcus R.
    Endocrinology; 1981 Mar 15; 108(3):831-5. PubMed ID: 6257497
    [Abstract] [Full Text] [Related]

  • 5. Conformational flexibility and biological activity of salmon calcitonin.
    Epand RM, Epand RF, Orlowski RC, Seyler JK, Colescott RL.
    Biochemistry; 1986 Apr 22; 25(8):1964-8. PubMed ID: 3707923
    [Abstract] [Full Text] [Related]

  • 6. A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats.
    Yates AJ, Gutierrez GE, Garrett IR, Mencel JJ, Nuss GW, Schreiber AB, Mundy GR.
    Endocrinology; 1990 Jun 22; 126(6):2845-9. PubMed ID: 2351097
    [Abstract] [Full Text] [Related]

  • 7. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
    Houssami S, Findlay DM, Brady CL, Martin TJ, Epand RM, Moore EE, Murayama E, Tamura T, Orlowski RC, Sexton PM.
    Mol Pharmacol; 1995 Apr 22; 47(4):798-809. PubMed ID: 7723741
    [Abstract] [Full Text] [Related]

  • 8. The hydrophobic moment of the amphipathic helix of salmon calcitonin and biological potency.
    Epand RM, Seyler JK, Orlowski RC.
    Eur J Biochem; 1986 Aug 15; 159(1):125-7. PubMed ID: 3743567
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions.
    Stroop SD, Nakamuta H, Kuestner RE, Moore EE, Epand RM.
    Endocrinology; 1996 Nov 15; 137(11):4752-6. PubMed ID: 8895343
    [Abstract] [Full Text] [Related]

  • 11. Structural and conformational requirements for human calcitonin activity: design, synthesis, and study of lactam-bridged analogues.
    Kapurniotu A, Taylor JW.
    J Med Chem; 1995 Mar 03; 38(5):836-47. PubMed ID: 7877149
    [Abstract] [Full Text] [Related]

  • 12. The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids.
    Epand RF, Orlowski RC, Epand RM.
    Biopolymers; 2004 Mar 03; 76(3):258-65. PubMed ID: 15148685
    [Abstract] [Full Text] [Related]

  • 13. Biologically active calcitonin analogs which have minimal interactions with phospholipids.
    Epand RM, Epand RF, Orlowski RC.
    Biochem Biophys Res Commun; 1988 Apr 15; 152(1):203-7. PubMed ID: 3358761
    [Abstract] [Full Text] [Related]

  • 14. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
    Taylor JW, Jin QK, Sbacchi M, Wang L, Belfiore P, Garnier M, Kazantzis A, Kapurniotu A, Zaratin PF, Scheideler MA.
    J Med Chem; 2002 Feb 28; 45(5):1108-21. PubMed ID: 11855991
    [Abstract] [Full Text] [Related]

  • 15. Presence of an amphipathic helical segment and its relationship to biological potency of calcitonin analogs.
    Epand RM, Epand RF, Orlowski RC.
    Int J Pept Protein Res; 1985 Jan 28; 25(1):105-11. PubMed ID: 3880517
    [Abstract] [Full Text] [Related]

  • 16. Conformational requirements for activity of salmon calcitonin.
    Findlay DM, Michelangeli VP, Martin TJ, Orlowski RC, Seyler JK.
    Endocrinology; 1985 Sep 28; 117(3):801-5. PubMed ID: 4017965
    [Abstract] [Full Text] [Related]

  • 17. Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions.
    Uda K, Kobayashi Y, Hisada T, Orlowski RC, Bastian JW, Arnaud CD, Wakabayashi K.
    Biol Pharm Bull; 1999 Mar 28; 22(3):244-52. PubMed ID: 10220278
    [Abstract] [Full Text] [Related]

  • 18. Biological activities and receptor interactions of des-Leu16 salmon and des-Phe16 human calcitonin.
    Findlay DM, Michelangeli VP, Orlowski RC, Martin TJ.
    Endocrinology; 1983 Apr 28; 112(4):1288-91. PubMed ID: 6299689
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and characterization of a model peptide having potent calcitonin-like biological activity: implications for calcitonin structure/activity.
    Moe GR, Kaiser ET.
    Biochemistry; 1985 Apr 09; 24(8):1971-6. PubMed ID: 2990546
    [Abstract] [Full Text] [Related]

  • 20. Structure-function studies of analogues of parathyroid hormone (PTH)-1-34 containing beta-amino acid residues in positions 11-13.
    Peggion E, Mammi S, Schievano E, Silvestri L, Schiebler L, Bisello A, Rosenblatt M, Chorev M.
    Biochemistry; 2002 Jun 25; 41(25):8162-75. PubMed ID: 12069609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.